CDC25B and hepatocellular carcinoma: Taken together, our data provide evidence that CDC25B may be a potential target for the clinical management of HCC: it is significantly over-expressed in HCC compared to non-tumor liver; the specific silencing of CDC25B expression inhibited HCC cell growth in vitro and in vivo, and also inhibited HCC cell migration and invasion in vitro.